Stocklytics Platform
Asset logo for symbol VKTX
Viking Therapeutics
VKTX53
$62.94arrow_drop_down6.19%-$4.16
Asset logo for symbol VKTX
VKTX53

$62.94

arrow_drop_down6.19%

AI Deep-Learning Forecast (VKTX)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Viking Therapeutics (VKTX) Stocklytics Forecast

Viking Therapeutics Inc. (VKTX) is a biopharmaceutical company that focuses on the development of novel therapeutics for the treatment of metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available small molecule thyroid hormone receptor agonist. The company is also developing VK0214, an orally available small molecule liver-selective thyroid hormone receptor agonist. These drug candidates have shown promising results in preclinical and clinical studies, and they have the potential to address significant unmet medical needs.
With the growing prevalence of metabolic and endocrine disorders, there is a strong demand for effective and safe treatment options. Viking Therapeutics Inc. is well-positioned to capitalize on this market opportunity with its innovative drug candidates. The company's pipeline also includes other promising candidates that target different indications within the metabolic and endocrine space. If its drug candidates continue to demonstrate positive results in clinical trials, Viking Therapeutics Inc. could see significant growth in the coming years.
add Viking Therapeutics  to watchlist

Keep an eye on Viking Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Viking Therapeutics (VKTX) stock?

Analysts have set a target price of $28.71 for Viking Therapeutics (VKTX), based on forecasts from 28 analysts. The predicted price range extends from a high of $50 to a low of $11. This represents a potential increase of up to -20.56% and a decrease of -82.52% from the current price of $62.94. These forecasts are as of 2022 Apr 28.
help

What are the analyst ratings for Viking Therapeutics (VKTX) stock?

The analyst ratings for Viking Therapeutics (VKTX) are distributed as follows: 3 analysts recommend buying, 0 have a neutral stance, and 0 suggest selling. There is a split consensus, with equal support for two of the rating categories. These ratings indicate the general sentiment among the analysts covering Viking Therapeutics .
help

What is the AI price prediction for Viking Therapeutics (VKTX) stock?

The AI price prediction model, leveraging machine-learning techniques, forecasts that Viking Therapeutics (VKTX) stock could reach $58.49 by 2024 Sep 30. This prediction indicates a potential price change of -7.07%. The forecast has a lifetime of 30 days, culminating on the target date provided. The prediction was made on 2024 Sep 09.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media